Blueprint Initiative

Blueprint Medicines is a global precision therapy company focused on developing transformative medicines for people with cancer and blood disorders. The company leverages a proprietary drug discovery platform to design highly selective small molecule inhibitors targeting genomic drivers of disease. Its commercial portfolio includes Ayvakit (avapritinib) for systemic mastocytosis and GIST, and Gavreto (pralsetinib) for RET-fusion positive cancers. Blueprint Medicines continues to advance a robust pipeline of kinase inhibitors and other targeted therapies across various stages of clinical development. The company is headquartered in Cambridge, Massachusetts, and maintains a strong focus on precision medicine and patient-centric innovation.